Telix Pharmaceuticals "Neuro-Oncology Event Highlights Potential..."

Research evidence excerpt

Telix Pharmaceuticals "Neuro-Oncology Event Highlights Potential..."

Global Research

30 June 2026ab

Telix Pharmaceuticals Equities

AustraliaNeuro-Oncology Event Highlights Potential

Opportunities for Pixclara and TLX101-Tx in Biotechnology

12-month rating BuyGBM

12m price target A$31.00

Key Takeaways Price (29 Jun 2026) A$16.17

TLX hosted a webinar highlighting the most recent developments in the neuro-oncology RIC: TLX.AX BBG: TLX AU

pipeline including TLX101-Tx (131I-iodofalan) and Pixclara (18F-FET) for the treatment

of glioblastomas (see webcast). Glioblastoma (GBM) is an aggressive brain cancer Trading data and key metrics

affecting ~12,000 patients/year, where the current standards of care do not provide 52-wk range A$25.39-8.63

meaningful long-term survival benefit (~12-15 months for 1L GBM). The event Market cap. A$5.41b/US$3.73b

highlighted 2 clinical assets with potential to transform the field - TLX-Tx and Pixclara Shares o/s 335m (ORD)

(TLX101-Px). We believe the Street has not assigned much credit to both programs, and Free float 72%

we expect Pixclara approval on Sept 11th (PDUFA date) to drive some upside while Avg. daily volume ('000) 2,317

clinical data from TLX101-Tx could drive long-term upside. Avg. daily value (m) A$33

TLX101-Tx is a novel radiolabeled small molecule targeting LAT1 (amino acid Common s/h equity (12/26E) US$0.47b

transporter) allowing it to cross the blood brain barrier and deliver targeted P/BV (12/26E) 8.0x

radiation to tumors. We think TLX101-Tx could provide meaningful benefits Net debt to EBITDA (12/26E) 2.0x

in recurrent GBM based on the impressive early efficacy (23-32 months mOS in

EPS (UBS, diluted) (USD)

Ph1 IPAX-1 and IPAX-Linz trials), a case study of complete remission in a refractory

UBS Cons.